---
title: "Darzalex (daratumumab) in multiple myeloma: Safety questions"
description: "Safety questions on Darzalex (daratumumab) in multiple myeloma, each answered with verbatim quotes from the manufacturer's US website for healthcare professionals or documents it links. Topics: Administration reactions, Warnings, and Side effects. Questions: Does Darzalex Faspro cause fewer infusion reactions than Darzalex IV (COLUMBA)? How common are infusion reactions with Darzalex IV? How are Darzalex infusion reactions managed? How common are Darzalex Faspro injection-site and systemic reactions? 15 further questions follow. 19 questions quoted from 5 sources."
canonical: "https://www.evicenter.com/medical-information/darzalex--multiple-myeloma/safety"
published: "2026-11-12T22:05:36-05:00"
modified: "2026-11-14T15:19:23-05:00"
---

# Darzalex (daratumumab) in multiple myeloma: Safety questions

Manufacturer: Janssen Biotech, Inc.  
Prescribing information: [Darzalex](https://www.janssenlabels.com/package-insert/product-monograph/prescribing-information/DARZALEX-pi.pdf), [Darzalex Faspro](https://www.janssenlabels.com/package-insert/product-monograph/prescribing-information/DARZALEX+Faspro-pi.pdf)

Questions that apply to every indication of Darzalex are on [Darzalex (daratumumab), all indications](https://www.evicenter.com/medical-information/darzalex).

## Administration reactions

<a id="darzalex-columba-infusion-reactions"></a>

### Does Darzalex Faspro cause fewer infusion reactions than Darzalex IV (COLUMBA)?

Applies to: Relapsed or refractory multiple myeloma after at least 3 prior lines: DARZALEX FASPRO vs intravenous DARZALEX monotherapy (COLUMBA)

> “Eligible patients were required to have relapsed or refractory multiple myeloma 
> who had received at least 3 prior lines of therapy including a proteasome 
> inhibitor and an immunomodulatory agent or who were double-refractory 
> to a proteasome inhibitor and an immunomodulatory agent.”

Source: [DARZALEX: DARZALEX FASPRO®, page 17, captured 2026-11-12](https://www.janssenlabels.com/package-insert/product-monograph/prescribing-information/DARZALEX+Faspro-pi.pdf#page=17)

> “Table 21: Adverse Reactions (≥10%) in Patients Who Received  
> DARZALEX FASPRO or Intravenous Daratumumab in COLUMBA
> Adverse Reaction
> DARZALEX FASPRO  
> (N=260)
> Intravenous Daratumumab 
> (N=258)
> All Grades 
> (%) 
> Grade ≥3 
> (%) 
> All Grades 
> (%) 
> Grade ≥3 
> (%)”

Source: [DARZALEX: DARZALEX FASPRO®, page 10, captured 2026-11-12](https://www.janssenlabels.com/package-insert/product-monograph/prescribing-information/DARZALEX+Faspro-pi.pdf#page=10)

> “Infusion reactions<sup>d</sup>
> 13
> 2<sup>#</sup>
> 34
> 5<sup>#</sup>”

Source: [DARZALEX: DARZALEX FASPRO®, page 10, captured 2026-11-12](https://www.janssenlabels.com/package-insert/product-monograph/prescribing-information/DARZALEX+Faspro-pi.pdf#page=10)

> “<sup>d</sup>	 Infusion reactions includes terms determined by investigators to be related 
> to infusion.”

Source: [DARZALEX: DARZALEX FASPRO®, page 10, captured 2026-11-12](https://www.janssenlabels.com/package-insert/product-monograph/prescribing-information/DARZALEX+Faspro-pi.pdf#page=10)

> “<sup>#</sup>	 Only Grade 3 adverse reactions occurred.”

Source: [DARZALEX: DARZALEX FASPRO®, page 10, captured 2026-11-12](https://www.janssenlabels.com/package-insert/product-monograph/prescribing-information/DARZALEX+Faspro-pi.pdf#page=10)

> “Most systemic ARRs were Grade 1 or 2 and occurred with the first injection. 
> The most common systemic ARRs (DARZALEX FASPRO<sup>®</sup>  vs DARZALEX<sup>®</sup>) were chills 
> (6% vs 12%), pyrexia (13% vs 13%), and dyspnea (6% vs 11%).
> Grade 3 systemic ARRs occurred in 2% of patients using DARZALEX FASPRO<sup>®</sup>  vs 5% 
> of those on DARZALEX<sup>®</sup>. 
> No Grade 4 systemic ARRs were reported.”

Source: [DARZALEX: DARZALEX FASPRO®, page 18, captured 2026-11-12](https://www.darzalexhcp.com/pdfs/dosing-and-administration-guide-faspro.pdf#page=18)

Note: Table 21 columns are DARZALEX FASPRO (N=260) All Grades and Grade ≥3, then intravenous daratumumab (N=258) All Grades and Grade ≥3 (%). The last passage is from the Dosing and Administration Guide; the Darzalex HCP FAQ describes the same COLUMBA comparison as systemic administration-related reactions in 13% (n=260) vs 34% (n=258).

<a id="darzalex-iv-infusion-reactions"></a>

### How common are infusion reactions with Darzalex IV?

> “DARZALEX can cause severe and/or serious infusion-related reactions 
> including anaphylactic reactions. These reactions can be life-threatening 
> and fatal outcomes have been reported [see Adverse Reactions (6.2)].
> In clinical trials (monotherapy and combination: N=2,066), infusion-
> related reactions occurred in 37% of patients with the Week 1 (16 mg/kg) 
> infusion, 2% with the Week 2 infusion, and cumulatively 6% with subsequent 
> infusions. Less than 1% of patients had a Grade 3/4 infusion-related reaction 
> at Week 2 or subsequent infusions. The median time to onset was 1.5 hours 
> (range: 0 to 73 hours). The incidence of infusion modification due to reactions 
> was 36%. Median durations of 16 mg/kg infusions for the Week 1, Week 2, 
> and subsequent infusions were approximately 7, 4, and 3 hours respectively. 
> Nearly all reactions occurred during infusion or within 4 hours of completing 
> DARZALEX. Prior to the introduction of post-infusion medication in clinical 
> trials, infusion-related reactions occurred up to 48 hours after infusion.
> Severe reactions have occurred, including bronchospasm, hypoxia, dyspnea, 
> hypertension, tachycardia, headache, laryngeal edema, pulmonary edema, 
> and ocular adverse reactions, including choroidal effusion, acute myopia, and 
> acute angle closure glaucoma. Signs and symptoms may include respiratory 
> symptoms, such as nasal congestion, cough, throat irritation, as well as chills, 
> vomiting and nausea. Less common signs and symptoms were wheezing, 
> allergic rhinitis, pyrexia, chest discomfort, pruritus, hypotension, and blurred 
> vision [see Adverse Reactions (6.1)].”

Source: [DARZALEX: DARZALEX®, page 4, captured 2026-11-12](https://www.janssenlabels.com/package-insert/product-monograph/prescribing-information/DARZALEX-pi.pdf#page=4)

> “Infusion-related reactions (IRRs) with DRd occurred in 41% of patients; 2% were Grade 3 and <1% were Grade 4<sup>1</sup>”

Source: [DARZALEX: DRd Side Effects, captured 2026-11-12](https://www.darzalexhcp.com/triplet/maia/safety/#:~:text=Infusion%2Drelated%20reactions%20%28IRRs%29%20with%20DRd,3%20and%20%3C1%25%20were%20Grade)

Note: The 41% rate is for DRd in MAIA, from the MAIA safety page.

<a id="darzalex-iv-infusion-reaction-management"></a>

### How are Darzalex infusion reactions managed?

> “For infusion-related reactions of any grade/severity, immediately interrupt 
> the DARZALEX infusion and manage symptoms. Management of infusion-
> related reactions may further require reduction in the rate of infusion, or 
> treatment discontinuation of DARZALEX as outlined below [see Warnings 
> and Precautions (5.1)].
> •	 Grade 1-2 (mild to moderate): Once reaction symptoms resolve, resume 
> the infusion at no more than half the rate at which the reaction occurred. 
> If the patient does not experience any further reaction symptoms, infusion 
> rate escalation may resume at increments and intervals as clinically 
> appropriate up to the maximum rate of 200 mL/hour (Table 6).
> •	 Grade 3 (severe): Once reaction symptoms resolve, consider restarting 
> the infusion at no more than half the rate at which the reaction occurred. 
> If the patient does not experience additional symptoms, resume infusion 
> rate escalation at increments and intervals as outlined in Table 6. Repeat 
> the procedure above in the event of recurrence of Grade 3 symptoms. 
> Permanently discontinue DARZALEX upon the third occurrence of a 
> Grade 3 or greater infusion-related reaction.
> •	 Grade 4 (life-threatening): Permanently discontinue DARZALEX.”

Source: [DARZALEX: DARZALEX®, page 3, captured 2026-11-12](https://www.janssenlabels.com/package-insert/product-monograph/prescribing-information/DARZALEX-pi.pdf#page=3)

> “Pre-medicate patients with antihistamines, antipyretics and corticosteroids. 
> Frequently monitor patients during the entire infusion [see Dosage and 
> Administration (2.3)]. Interrupt DARZALEX infusion for reactions of any severity 
> and institute medical management as needed. Permanently discontinue 
> DARZALEX therapy if an anaphylactic reaction or life-threatening (Grade 4) 
> reaction occurs and institute appropriate emergency care. For patients with 
> Grade 1, 2, or 3 reactions, reduce the infusion rate when re-starting the infusion 
> [see Dosage and Administration (2.4)].
> To reduce the risk of delayed infusion-related reactions, administer oral 
> corticosteroids to all patients following DARZALEX infusions [see Dosage 
> and Administration (2.3)]. Patients with a history of chronic obstructive 
> pulmonary disease may require additional post-infusion medications to 
> manage respiratory complications. Consider prescribing short- and long-
> acting bronchodilators and inhaled corticosteroids for patients with chronic 
> obstructive pulmonary disease [see Dosage and Administration (2.3)].”

Source: [DARZALEX: DARZALEX®, page 4, captured 2026-11-12](https://www.janssenlabels.com/package-insert/product-monograph/prescribing-information/DARZALEX-pi.pdf#page=4)

<a id="darzalex-faspro-administration-reactions"></a>

### How common are Darzalex Faspro injection-site and systemic reactions?

> “In a pooled safety population of 1446 patients with multiple myeloma (N=1253) 
> or light chain (AL) amyloidosis (N=193) who received DARZALEX FASPRO as 
> monotherapy or as part of a combination therapy, 7% of patients experienced 
> a systemic administration-related reaction (Grade 2: 3%, Grade 3: 0.8%, 
> Grade 4: 0.1%). In patients with high-risk smoldering multiple myeloma (N=193), 
> systemic administration-related reactions occurred in 17% of patients in 
> AQUILA (Grade 2: 7%, Grade 3: 1%).
> In all patients (N=1639), systemic administration-related reactions occurred 
> in 7% of patients with the first injection, 0.5% with the second injection, and 
> cumulatively 1% with subsequent injections. The median time to onset was 
> 3.2 hours (range: 4 minutes to 3.5 days). Of the 283 systemic administration-
> related reactions that occurred in 135 patients, 240 (85%) occurred on the 
> day of DARZALEX FASPRO administration. Delayed systemic administration-
> related reactions have occurred in 1% of the patients.”

Source: [DARZALEX: DARZALEX FASPRO®, page 4, captured 2026-11-12](https://www.janssenlabels.com/package-insert/product-monograph/prescribing-information/DARZALEX+Faspro-pi.pdf#page=4)

> “Severe reactions include hypoxia, dyspnea, hypertension, and tachycardia, 
> and ocular adverse reactions, including choroidal effusion, acute myopia, 
> and acute angle closure glaucoma. Other signs and symptoms of systemic 
> administration-related reactions may include respiratory symptoms, such as 
> bronchospasm, nasal congestion, cough, throat irritation, allergic rhinitis, 
> and wheezing, as well as anaphylactic reaction, pyrexia, chest pain, pruritus, 
> chills, vomiting, nausea, hypotension, and blurred vision.”

Source: [DARZALEX: DARZALEX FASPRO®, page 4, captured 2026-11-12](https://www.janssenlabels.com/package-insert/product-monograph/prescribing-information/DARZALEX+Faspro-pi.pdf#page=4)

> “Pre-medicate patients with histamine-1 receptor antagonist, acetaminophen 
> and corticosteroids [see Dosage and Administration (2.6)]. Monitor patients 
> for systemic administration-related reactions, especially following the first 
> and second injections. For anaphylactic reaction or life-threatening (Grade 4) 
> administration-related reactions, immediately and permanently discontinue 
> DARZALEX  FASPRO. Consider administering corticosteroids and other 
> medications after the administration of DARZALEX FASPRO depending on 
> dosing regimen and medical history to minimize the risk of delayed (defined 
> as occurring the day after administration) systemic administration-related 
> reactions [see Dosage and Administration (2.6)].”

Source: [DARZALEX: DARZALEX FASPRO®, page 4, captured 2026-11-12](https://www.janssenlabels.com/package-insert/product-monograph/prescribing-information/DARZALEX+Faspro-pi.pdf#page=4)

> “In this pooled safety population of 1446 patients with multiple myeloma 
> (N=1253) or light chain (AL) amyloidosis (N=193), injection-site reactions 
> occurred in 8% of patients, including Grade 2 reactions in 1.1%. The most 
> frequent (>1%) injection-site reactions were injection site erythema and 
> injection site rash. In patients with high-risk smoldering multiple myeloma 
> (N=193), injection-site reactions occurred in 28% of patients, including Grade 2 
> reactions in 3%. These local reactions occurred a median of 6 minutes (range: 
> 0 minutes to 6.5 days) after starting administration of DARZALEX FASPRO. 
> Monitor for local reactions and consider symptomatic management.”

Source: [DARZALEX: DARZALEX FASPRO®, page 4, captured 2026-11-12](https://www.janssenlabels.com/package-insert/product-monograph/prescribing-information/DARZALEX+Faspro-pi.pdf#page=4)

Note: The Important Safety Information on the Darzalex HCP pages gives the multiple myeloma count in the systemic-reaction sentence as N=1235; the Prescribing Information gives N=1253.

## Warnings

<a id="darzalex-ocular-reactions"></a>

### Can Darzalex cause eye problems such as acute myopia or angle-closure glaucoma?

> “Ocular adverse reactions, including acute myopia and narrowing of the anterior 
> chamber angle due to ciliochoroidal effusions with potential for increased 
> intraocular pressure or glaucoma, have occurred with daratumumab-containing 
> products. If ocular symptoms occur, interrupt DARZALEX FASPRO and seek 
> immediate ophthalmologic evaluation prior to restarting DARZALEX FASPRO.”

Source: [DARZALEX: DARZALEX FASPRO®, page 4, captured 2026-11-12](https://www.janssenlabels.com/package-insert/product-monograph/prescribing-information/DARZALEX+Faspro-pi.pdf#page=4)

> “Ocular adverse reactions, including acute myopia and narrowing of the 
> anterior chamber angle due to ciliochoroidal effusions with potential for 
> increased intraocular pressure or glaucoma, have occurred with DARZALEX 
> infusion. If ocular symptoms occur, interrupt DARZALEX infusion and seek 
> immediate ophthalmologic evaluation prior to restarting DARZALEX.”

Source: [DARZALEX: DARZALEX®, page 4, captured 2026-11-12](https://www.janssenlabels.com/package-insert/product-monograph/prescribing-information/DARZALEX-pi.pdf#page=4)

<a id="darzalex-neutropenia-thrombocytopenia"></a>

### Does Darzalex increase the risk of low blood counts (neutropenia or thrombocytopenia)?

> “5.4	 Neutropenia
> DARZALEX may increase neutropenia induced by background therapy [see 
> Adverse Reactions (6.1)].
> Monitor complete blood cell counts periodically during treatment according 
> to manufacturer’s prescribing information for background therapies. Monitor 
> patients with neutropenia for signs of infection. Consider withholding 
> DARZALEX until recovery of neutrophils.
> 5.5	 Thrombocytopenia
> DARZALEX may increase thrombocytopenia induced by background therapy 
> [see Adverse Reactions (6.1)].
> Monitor complete blood cell counts periodically during treatment according 
> to manufacturer’s prescribing information for background therapies. Consider 
> withholding DARZALEX until recovery of platelets.”

Source: [DARZALEX: DARZALEX®, page 4, captured 2026-11-12](https://www.janssenlabels.com/package-insert/product-monograph/prescribing-information/DARZALEX-pi.pdf#page=4)

> “5.4	 Neutropenia
> Daratumumab may increase neutropenia induced by background therapy [see 
> Adverse Reactions (6.1)].
> Monitor complete blood cell counts periodically during treatment according 
> to manufacturer’s prescribing information for background therapies. Monitor 
> patients with neutropenia for signs of infection. Consider withholding 
> DARZALEX  FASPRO until recovery of neutrophils. In lower body weight 
> patients receiving DARZALEX FASPRO, higher rates of Grade 3-4 neutropenia 
> were observed.”

Source: [DARZALEX: DARZALEX FASPRO®, page 4, captured 2026-11-12](https://www.janssenlabels.com/package-insert/product-monograph/prescribing-information/DARZALEX+Faspro-pi.pdf#page=4)

> “5.5	 Thrombocytopenia
> Daratumumab may increase thrombocytopenia induced by background 
> therapy [see Adverse Reactions (6.1)].”

Source: [DARZALEX: DARZALEX FASPRO®, page 4, captured 2026-11-12](https://www.janssenlabels.com/package-insert/product-monograph/prescribing-information/DARZALEX+Faspro-pi.pdf#page=4)

> “Monitor complete blood cell counts periodically during treatment according 
> to manufacturer’s prescribing information for background therapies. Consider 
> withholding DARZALEX FASPRO until recovery of platelets.”

Source: [DARZALEX: DARZALEX FASPRO®, page 5, captured 2026-11-12](https://www.janssenlabels.com/package-insert/product-monograph/prescribing-information/DARZALEX+Faspro-pi.pdf#page=5)

> “2.7	 Dosage Modifications for Adverse Reactions
> No dose reductions of DARZALEX FASPRO are recommended. Consider 
> withholding DARZALEX FASPRO to allow recovery of blood cell counts in the 
> event of myelosuppression [see Warnings and Precautions (5.4, 5.5)].”

Source: [DARZALEX: DARZALEX FASPRO®, page 4, captured 2026-11-12](https://www.janssenlabels.com/package-insert/product-monograph/prescribing-information/DARZALEX+Faspro-pi.pdf#page=4)

> “Table 8: Treatment-Emergent Hematology Laboratory Abnormalities in MAIA
> DRd (N=364)
> Rd (N=365)
> All 
> Grades 
> (%)
> Grade 3 
> (%) 
> Grade 4 
> (%)
> All 
> Grades 
> (%)
> Grade 3 
> (%) 
> Grade 4 
> (%)
> Leukopenia
> 90
> 30
> 5
> 82
> 20
> 4
> Neutropenia
> 91
> 39
> 17
> 77
> 28
> 11
> Lymphopenia
> 84
> 41
> 11
> 75
> 36
> 6
> Thrombocytopenia
> 67
> 6
> 3
> 58
> 7
> 4
> Anemia
> 47
> 13
> 0
> 57
> 24
> 0”

Source: [DARZALEX: DARZALEX®, page 5, captured 2026-11-12](https://www.janssenlabels.com/package-insert/product-monograph/prescribing-information/DARZALEX-pi.pdf#page=5)

> “Table 10: Select Laboratory Abnormalities (≥30%) That Worsened from 
> Baseline in Patients Who Received DARZALEX FASPRO-VRd 
> through the End of Consolidation in PERSEUS
> Laboratory 
> Abnormality
> DARZALEX FASPRO-VRd<sup>a</sup>
> VRd<sup>a</sup> 
> All Grades 
> (%)
> Grade 3 or4
> (%)
> All Grades
> (%)
> Grade 3 or 4
> (%)
> Hematology
> Decreased platelets
> 89
> 34
> 78
> 25
> Decreased lymphocytes
> 87
> 69
> 69
> 43
> Decreased leukocytes
> 78
> 47
> 56
> 22
> Decreased neutrophils
> 67
> 52
> 47
> 34
> Decreased hemoglobin
> 39
> 7
> 43
> 6
> Chemistry
> Increased alanine 
> aminotransferase (ALT)
> 52
> 7
> 48
> 5
> Decreased sodium
> 40
> 5
> 25
> 5
> Increased alkaline 
> phosphatase
> 39
> 0
> 36
> 1
> Decreased potassium
> 30
> 6
> 24
> 3
> Key: VRd=bortezomib-lenalidomide-dexamethasone
> <sup>a</sup>	 Denominator is based on number of subjects with a baseline and 
> post-baseline laboratory value for each laboratory test: N=351 for 
> DARZALEX FASPRO-VRd and N=346 for VRd.”

Source: [DARZALEX: DARZALEX FASPRO®, page 6, captured 2026-11-12](https://www.janssenlabels.com/package-insert/product-monograph/prescribing-information/DARZALEX+Faspro-pi.pdf#page=6)

Note: The first passage is from the DARZALEX (intravenous) Prescribing Information; the next four are from the DARZALEX FASPRO Prescribing Information. Table 8 (MAIA) columns are DRd (N=364) All Grades, Grade 3, and Grade 4, then Rd (N=365) All Grades, Grade 3, and Grade 4 (%). Table 10 (PERSEUS) columns are DARZALEX FASPRO-VRd All Grades and Grade 3 or 4, then VRd All Grades and Grade 3 or 4 (%).

<a id="darzalex-infections"></a>

### Does Darzalex increase the risk of serious infections?

> “5.3	 Infections
> DARZALEX can cause serious, life-threatening, or fatal infections. In patients 
> who received DARZALEX in a pooled safety population (N=2066), serious 
> infections, including opportunistic infections, occurred in 22.6% of patients, 
> Grade 3 or 4 infections occurred in 24.3%, and fatal infections occurred in 1.2%. 
> The most common (≥2%) types of serious infection reported were pneumonia 
> (11%), upper respiratory tract infection (4%), sepsis (3%), and bronchitis (2%).
> Monitor patients for signs and symptoms of infection prior to and during 
> treatment with DARZALEX and treat appropriately. Administer prophylactic 
> antimicrobials according to guidelines [see Dosage and Administration (2.3)].”

Source: [DARZALEX: DARZALEX®, page 4, captured 2026-11-12](https://www.janssenlabels.com/package-insert/product-monograph/prescribing-information/DARZALEX-pi.pdf#page=4)

> “5.3	 Infections
> DARZALEX FASPRO can cause serious, life-threatening, or fatal infections. 
> In patients who received DARZALEX FASPRO in a pooled safety population 
> including patients with smoldering multiple myeloma and light chain (AL) 
> amyloidosis (N=1639), serious infections, including opportunistic infections, 
> occurred in 24% of patients, Grade 3 or 4 infections occurred in 22%, and 
> fatal infections occurred in 2.5%. The most common type of serious infection 
> reported was pneumonia (8.5%).
> Monitor patients for signs and symptoms of infection prior to and during 
> treatment with DARZALEX FASPRO and treat appropriately. Administer 
> prophylactic antimicrobials according to guidelines [see Dosage and 
> Administration (2.6)].”

Source: [DARZALEX: DARZALEX FASPRO®, page 4, captured 2026-11-12](https://www.janssenlabels.com/package-insert/product-monograph/prescribing-information/DARZALEX+Faspro-pi.pdf#page=4)

> “Serious adverse reactions with a 2% greater incidence in the DRd arm 
> compared to the Rd arm were pneumonia (DRd 15% vs Rd 8%), bronchitis 
> (DRd 4% vs Rd 2%) and dehydration (DRd 2% vs Rd <1%).”

Source: [DARZALEX: DARZALEX®, page 5, captured 2026-11-12](https://www.janssenlabels.com/package-insert/product-monograph/prescribing-information/DARZALEX-pi.pdf#page=5)

> “You are now viewing a follow-up analysis of the MAIA study. This information is not included in the current Prescribing Information and has not been evaluated by the FDA. TEAEs are reported as observed. The follow-up analysis was not adjusted for multiplicity and conclusions should not be drawn.”

Source: [DARZALEX: DRd Side Effects, captured 2026-11-12](https://www.darzalexhcp.com/triplet/maia/safety/#:~:text=You%20are%20now%20viewing%20a,conclusions%20should%20not%20be%20drawn.)

> “Cumulative Grade 3/4 infection rates were 43% for DRd vs 30% for Rd<sup>3†</sup>”

Source: [DARZALEX: DRd Side Effects, captured 2026-11-12](https://www.darzalexhcp.com/triplet/maia/safety/#:~:text=Cumulative%20Grade%203%2F4%20infection%20rates%20were%2043%25%20for%20DRd%20vs%2030%25%20for)

> “<sup>*</sup>Median follow-up was 64.5 months.<sup>3</sup>”

Source: [DARZALEX: DRd Side Effects, captured 2026-11-12](https://www.darzalexhcp.com/triplet/maia/safety/#:~:text=follow%2Dup%20was%2064.5)

Note: The first passage is from the DARZALEX (intravenous) Prescribing Information; the second is from the DARZALEX FASPRO Prescribing Information, whose pooled population includes smoldering multiple myeloma and AL amyloidosis. The third passage is from the MAIA safety section of the DARZALEX Prescribing Information; the cumulative infection rates are from the follow-up safety analysis on the MAIA safety page.

<a id="darzalex-blood-typing-interference"></a>

### Does Darzalex interfere with blood typing and transfusion tests?

> “5.7	 Interference with Serological Testing
> Daratumumab binds to CD38 on red blood cells (RBCs) and results in a positive 
> Indirect Antiglobulin Test (Indirect Coombs test). Daratumumab-mediated 
> positive indirect antiglobulin test may persist for up to 6 months after the last 
> daratumumab administration. Daratumumab bound to RBCs masks detection 
> of antibodies to minor antigens in the patient’s serum [see References (15)]. 
> The determination of a patient’s ABO and Rh blood type are not impacted [see 
> Drug Interactions (7.1)].
> Notify blood transfusion centers of this interference with serological testing 
> and inform blood banks that a patient has received DARZALEX FASPRO. Type 
> and screen patients prior to starting DARZALEX FASPRO [see Dosage and 
> Administration (2.1)].”

Source: [DARZALEX: DARZALEX FASPRO®, page 5, captured 2026-11-12](https://www.janssenlabels.com/package-insert/product-monograph/prescribing-information/DARZALEX+Faspro-pi.pdf#page=5)

> “Interference with Indirect Antiglobulin Tests (Indirect Coombs Test)
> Daratumumab binds to CD38 on RBCs and interferes with compatibility testing, 
> including antibody screening and cross matching. Daratumumab interference 
> mitigation methods include treating reagent RBCs with dithiothreitol (DTT) to 
> disrupt daratumumab binding [see References (15)] or genotyping. Since the 
> Kell blood group system is also sensitive to DTT treatment, supply K-negative 
> units after ruling out or identifying alloantibodies using DTT-treated RBCs.
> If an emergency transfusion is required, administer non-cross-matched ABO/
> RhD-compatible RBCs per local blood bank practices.”

Source: [DARZALEX: DARZALEX FASPRO®, page 12, captured 2026-11-12](https://www.janssenlabels.com/package-insert/product-monograph/prescribing-information/DARZALEX+Faspro-pi.pdf#page=12)

> “DARZALEX<sup>®</sup> binds to CD38 found on red blood cells (RBCs) and results in a positive indirect antiglobulin test (indirect Coombs test) that may persist for up to 6 months after the last DARZALEX<sup>®</sup> infusion.
>
> Type and screen patients before starting DARZALEX<sup>®</sup>
>
> Identify any blood samples of patients treated with
> DARZALEX<sup>®</sup>
>
> Inform blood banks when a patient is on DARZALEX<sup>®</sup>
>
> Ask patients to tell other healthcare professionals that they’ve taken DARZALEX<sup>®</sup>”

Source: [DARZALEX: DRd Side Effects, captured 2026-11-12](https://www.darzalexhcp.com/triplet/maia/safety/#:~:text=binds%20to%20CD38%20found%20on,healthcare%20professionals%20that%20they%E2%80%99ve%20taken)

<a id="darzalex-complete-response-interference"></a>

### Does Darzalex interfere with myeloma response tests (SPE and immunofixation)?

> “5.6	 Interference with Determination of Complete Response
> Daratumumab is a human IgG kappa monoclonal antibody that can be 
> detected on both, the serum protein electrophoresis (SPE) and immunofixation 
> (IFE) assays used for the clinical monitoring of endogenous M-protein [see 
> Drug Interactions (7.1)]. This interference can impact the determination of 
> complete response and of disease progression in some patients with IgG 
> kappa myeloma protein.”

Source: [DARZALEX: DARZALEX®, page 4, captured 2026-11-12](https://www.janssenlabels.com/package-insert/product-monograph/prescribing-information/DARZALEX-pi.pdf#page=4)

> “5.8	 Interference with Determination of Complete Response
> Daratumumab is a human IgG kappa monoclonal antibody that can be 
> detected on both the serum protein electrophoresis (SPE) and immunofixation 
> (IFE) assays used for the clinical monitoring of endogenous M-protein [see 
> Drug Interactions (7.1)]. This interference can impact the determination of 
> complete response and of disease progression in some DARZALEX FASPRO-
> treated patients with IgG kappa myeloma protein.”

Source: [DARZALEX: DARZALEX FASPRO®, page 5, captured 2026-11-12](https://www.janssenlabels.com/package-insert/product-monograph/prescribing-information/DARZALEX+Faspro-pi.pdf#page=5)

> “Interference with Serum Protein Electrophoresis and Immunofixation Tests
> Daratumumab may be detected on serum protein electrophoresis (SPE) 
> and immunofixation (IFE) assays used for monitoring disease monoclonal 
> immunoglobulins (M protein). False positive SPE and IFE assay results 
> may occur for patients with IgG kappa myeloma protein impacting initial 
> assessment of complete responses by International Myeloma Working 
> Group (IMWG) criteria. In DARZALEX  FASPRO-treated patients with 
> persistent very good partial response, where daratumumab interference is 
> suspected, consider using a FDA-approved daratumumab-specific IFE assay 
> to distinguish daratumumab from any remaining endogenous M protein in the 
> patient’s serum, to facilitate determination of a complete response.”

Source: [DARZALEX: DARZALEX FASPRO®, page 12, captured 2026-11-12](https://www.janssenlabels.com/package-insert/product-monograph/prescribing-information/DARZALEX+Faspro-pi.pdf#page=12)

Note: The first passage is from the DARZALEX (intravenous) Prescribing Information; the others are from the DARZALEX FASPRO Prescribing Information.

<a id="darzalex-faspro-cardiac-toxicity"></a>

### Can Darzalex Faspro cause heart problems in light chain (AL) amyloidosis?

Applies to: Light chain (AL) amyloidosis treated with DARZALEX FASPRO + bortezomib, cyclophosphamide, and dexamethasone

> “5.2	 Cardiac Toxicity in Patients with Light Chain (AL) Amyloidosis
> Serious or fatal cardiac adverse reactions occurred in patients with light 
> chain (AL) amyloidosis who received DARZALEX FASPRO in combination with 
> bortezomib, cyclophosphamide and dexamethasone [see Adverse Reactions 
> (6.1)]. Serious cardiac disorders occurred in 16% and fatal cardiac disorders 
> occurred in 10% of patients. Patients with NYHA Class IIIA or Mayo Stage IIIA 
> disease may be at greater risk. Patients with NYHA Class IIIB or IV disease 
> were not studied.
> Monitor patients with cardiac involvement of light chain (AL) amyloidosis more 
> frequently for cardiac adverse reactions and administer supportive care as 
> appropriate.”

Source: [DARZALEX: DARZALEX FASPRO®, page 4, captured 2026-11-12](https://www.janssenlabels.com/package-insert/product-monograph/prescribing-information/DARZALEX+Faspro-pi.pdf#page=4)

> “DARZALEX FASPRO is not indicated and is not recommended for the treatment 
> of patients with light chain (AL) amyloidosis who have NYHA Class IIIB or 
> Class IV cardiac disease or Mayo Stage IIIB outside of controlled clinical trials 
> [see Warnings and Precautions (5.2)].”

Source: [DARZALEX: DARZALEX FASPRO®, page 2, captured 2026-11-12](https://www.janssenlabels.com/package-insert/product-monograph/prescribing-information/DARZALEX+Faspro-pi.pdf#page=2)

Note: Warning 5.2 of the DARZALEX FASPRO label applies to light chain (AL) amyloidosis treated with bortezomib, cyclophosphamide, and dexamethasone.

<a id="darzalex-pregnancy-contraception"></a>

### Can Darzalex be used during pregnancy?

> “5.7	 Embryo-Fetal Toxicity
> Based on the mechanism of action, DARZALEX can cause fetal harm when 
> administered to a pregnant woman. DARZALEX may cause depletion of fetal 
> immune cells and decreased bone density. Advise pregnant women of the 
> potential risk to a fetus. Advise females with reproductive potential to use 
> effective contraception during treatment with DARZALEX and for 3 months 
> after the last dose [see Use in Specific Populations (8.1, 8.3)].
> The combination of DARZALEX with lenalidomide, pomalidomide, or 
> thalidomide is contraindicated in pregnant women, because lenalidomide, 
> pomalidomide, and thalidomide may cause birth defects and death of the 
> unborn child. Refer to the lenalidomide, pomalidomide, or thalidomide 
> prescribing information on use during pregnancy.”

Source: [DARZALEX: DARZALEX®, page 4, captured 2026-11-12](https://www.janssenlabels.com/package-insert/product-monograph/prescribing-information/DARZALEX-pi.pdf#page=4)

> “5.6	 Embryo-Fetal Toxicity
> Based on the mechanism of action, DARZALEX FASPRO can cause fetal harm 
> when administered to a pregnant woman. DARZALEX FASPRO may cause 
> depletion of fetal immune cells and decreased bone density. Advise pregnant 
> women of the potential risk to a fetus. Advise females with reproductive potential 
> to use effective contraception during treatment with DARZALEX FASPRO and for 
> 3 months after the last dose [see Use in Specific Populations (8.1, 8.3)].
> The combination of DARZALEX FASPRO with lenalidomide, thalidomide or 
> pomalidomide is contraindicated in pregnant women, because lenalidomide, 
> thalidomide or pomalidomide may cause birth defects and death of the unborn 
> child. Refer to the lenalidomide, thalidomide or pomalidomide prescribing 
> information on use during pregnancy.”

Source: [DARZALEX: DARZALEX FASPRO®, page 5, captured 2026-11-12](https://www.janssenlabels.com/package-insert/product-monograph/prescribing-information/DARZALEX+Faspro-pi.pdf#page=5)

Note: The first passage is from the DARZALEX (intravenous) Prescribing Information; the second is from the DARZALEX FASPRO Prescribing Information.

<a id="darzalex-contraception"></a>

### How long is contraception needed after the last dose of Darzalex?

> “Contraception
> Advise females of reproductive potential to use effective contraception during 
> treatment with DARZALEX and for 3 months after the last dose. Additionally, 
> refer to the lenalidomide, pomalidomide, or thalidomide labeling for additional 
> recommendations for contraception.”

Source: [DARZALEX: DARZALEX®, page 10, captured 2026-11-12](https://www.janssenlabels.com/package-insert/product-monograph/prescribing-information/DARZALEX-pi.pdf#page=10)

> “Contraception
> Advise females of reproductive potential to use effective contraception during 
> treatment with DARZALEX FASPRO and for 3 months after the last dose. 
> Additionally, refer to the lenalidomide, thalidomide or pomalidomide labeling 
> for additional recommendations for contraception.”

Source: [DARZALEX: DARZALEX FASPRO®, page 13, captured 2026-11-12](https://www.janssenlabels.com/package-insert/product-monograph/prescribing-information/DARZALEX+Faspro-pi.pdf#page=13)

Note: The first passage is from the DARZALEX (intravenous) Prescribing Information; the second is from the DARZALEX FASPRO Prescribing Information.

<a id="darzalex-contraindications"></a>

### Who should not receive Darzalex (contraindications)?

> “DARZALEX FASPRO is contraindicated in patients with a history of severe 
> hypersensitivity to daratumumab, hyaluronidase or any of the components of the 
> formulation [see Warnings and Precautions (5.1) and Adverse Reactions (6.2)].”

Source: [DARZALEX: DARZALEX FASPRO®, page 4, captured 2026-11-12](https://www.janssenlabels.com/package-insert/product-monograph/prescribing-information/DARZALEX+Faspro-pi.pdf#page=4)

> “DARZALEX is contraindicated in patients with a history of severe 
> hypersensitivity (e.g. anaphylactic reactions) to daratumumab or any of the 
> components of the formulation [see Warnings and Precautions (5.1)].”

Source: [DARZALEX: DARZALEX®, page 4, captured 2026-11-12](https://www.janssenlabels.com/package-insert/product-monograph/prescribing-information/DARZALEX-pi.pdf#page=4)

## Side effects

<a id="darzalex-maia-side-effects"></a>

### What are the most common side effects of Darzalex (DRd) in MAIA?

Applies to: Newly diagnosed multiple myeloma, ineligible for autologous stem cell transplant: DARZALEX + lenalidomide + dexamethasone (DRd) vs Rd (MAIA)

> “The safety of DARZALEX in combination with lenalidomide and dexamethasone 
> was evaluated in MAIA [see Clinical Studies (14.1)]. Adverse reactions described 
> in Table 7 reflect exposure to DARZALEX for a median treatment duration 
> of 25.3 months (range: 0.1 to 40.44 months) for daratumumab-lenalidomide-
> dexamethasone (DRd) and of 21.3 months (range: 0.03 to 40.64 months) for 
> lenalidomide-dexamethasone (Rd).”

Source: [DARZALEX: DARZALEX®, page 4, captured 2026-11-12](https://www.janssenlabels.com/package-insert/product-monograph/prescribing-information/DARZALEX-pi.pdf#page=4)

> “Serious adverse reactions with a 2% greater incidence in the DRd arm 
> compared to the Rd arm were pneumonia (DRd 15% vs Rd 8%), bronchitis 
> (DRd 4% vs Rd 2%) and dehydration (DRd 2% vs Rd <1%).”

Source: [DARZALEX: DARZALEX®, page 5, captured 2026-11-12](https://www.janssenlabels.com/package-insert/product-monograph/prescribing-information/DARZALEX-pi.pdf#page=5)

> “Table 7: Adverse Reactions Reported in ≥10% of Patients and With at Least 
> a 5% Greater Frequency in the DRd Arm in MAIA
> Body System 
> Adverse Reaction
> DRd (N=364)
> Rd (N=365)
> All 
> Grades 
> (%)
> Grade 3 
> (%)
> Grade 4 
> (%)
> All 
> Grades 
> (%)
> Grade 3 
> (%)
> Grade 4 
> (%)
> Gastrointestinal disorders
> Diarrhea
> 57
> 7
> 0
> 46
> 4
> 0
> Constipation
> 41
> 1
> <1
> 36
> <1
> 0
> Nausea
> 32
> 1
> 0
> 23
> 1
> 0
> Vomiting
> 17
> 1
> 0
> 12
> <1
> 0
> Infections
> Upper respiratory 
> tract infection<sup>a</sup>
> 52
> 2
> <1
> 36
> 2
> <1
> Bronchitis<sup>b</sup>
> 29
> 3
> 0
> 21
> 1
> 0
> Pneumonia<sup>c</sup>
> 26
> 14
> 1
> 14
> 7
> 1
> Urinary tract 
> infection
> 18
> 2
> 0
> 10
> 2
> 0
> General disorders and administration site conditions
> Infusion-related 
> reactions<sup>d</sup>
> 41
> 2
> <1
> 0
> 0
> 0
> Peripheral edema<sup>e</sup>
> 41
> 2
> 0
> 33
> 1
> 0
> Fatigue
> 40
> 8
> 0
> 28
> 4
> 0
> Asthenia
> 32
> 4
> 0
> 25
> 3
> <1
> Pyrexia
> 23
> 2
> 0
> 18
> 2
> 0
> Chills
> 13
> 0
> 0
> 2
> 0
> 0
> Musculoskeletal and connective tissue disorders
> Back pain
> 34
> 3
> <1
> 26
> 3
> <1
> Muscle spasms
> 29
> 1
> 0
> 22
> 1
> 0
> Respiratory, thoracic and mediastinal disorders
> Dyspnea<sup>f</sup>
> 32
> 3
> <1
> 20
> 1
> 0
> Cough<sup>g</sup>
> 30
> <1
> 0
> 18
> 0
> 0
> Nervous system disorders
> Peripheral sensory 
> neuropathy
> 24
> 1
> 0
> 15
> 0
> 0
> Headache
> 19
> 1
> 0
> 11
> 0
> 0
> Paresthesia
> 16
> 0
> 0
> 8
> 0
> 0
> Metabolism and nutrition disorders
> Decreased appetite 22
> 1
> 0
> 15
> <1
> <1
> Hyperglycemia
> 14
> 6
> 1
> 8
> 3
> 1
> Hypocalcemia
> 14
> 1
> <1
> 9
> 1
> 1
> Vascular disorders
> Hypertension<sup>h</sup>
> 13
> 6
> <1
> 7
> 4
> 0”

Source: [DARZALEX: DARZALEX®, page 5, captured 2026-11-12](https://www.janssenlabels.com/package-insert/product-monograph/prescribing-information/DARZALEX-pi.pdf#page=5)

> “<sup>d</sup>	 Infusion-related reaction includes terms determined by investigators to be 
> related to infusion”

Source: [DARZALEX: DARZALEX®, page 5, captured 2026-11-12](https://www.janssenlabels.com/package-insert/product-monograph/prescribing-information/DARZALEX-pi.pdf#page=5)

> “Table 8: Treatment-Emergent Hematology Laboratory Abnormalities in MAIA
> DRd (N=364)
> Rd (N=365)
> All 
> Grades 
> (%)
> Grade 3 
> (%) 
> Grade 4 
> (%)
> All 
> Grades 
> (%)
> Grade 3 
> (%) 
> Grade 4 
> (%)
> Leukopenia
> 90
> 30
> 5
> 82
> 20
> 4
> Neutropenia
> 91
> 39
> 17
> 77
> 28
> 11
> Lymphopenia
> 84
> 41
> 11
> 75
> 36
> 6
> Thrombocytopenia
> 67
> 6
> 3
> 58
> 7
> 4
> Anemia
> 47
> 13
> 0
> 57
> 24
> 0”

Source: [DARZALEX: DARZALEX®, page 5, captured 2026-11-12](https://www.janssenlabels.com/package-insert/product-monograph/prescribing-information/DARZALEX-pi.pdf#page=5)

Note: Table 7 columns are DRd (N=364) All Grades, Grade 3, and Grade 4, then Rd (N=365) All Grades, Grade 3, and Grade 4 (%). In the decreased appetite row, the label and the DRd All Grades value share one line. Table 8 columns follow the same order.

<a id="darzalex-cepheus-side-effects"></a>

### What are the side effects of Darzalex Faspro with VRd for transplant-ineligible patients (CEPHEUS)?

Applies to: Newly diagnosed multiple myeloma, ineligible for autologous stem cell transplant: DARZALEX FASPRO + bortezomib, lenalidomide, dexamethasone (DVRd) vs VRd (CEPHEUS)

> “The safety of DARZALEX FASPRO in combination with bortezomib, lenalidomide and 
> dexamethasone compared to bortezomib, lenalidomide and dexamethasone (VRd) 
> was evaluated in CEPHEUS in patients with newly diagnosed multiple myeloma who 
> were ineligible for ASCT or refused ASCT as initial therapy [see Clinical Studies 
> (14.1)]. Patients received DARZALEX FASPRO 1,800 mg/30,000 units administered 
> subcutaneously once weekly from weeks 1 to 6, once every 3 weeks from weeks 
> 7 to 24 and once every 4 weeks starting with week 25 until disease progression or 
> unacceptable toxicity in combination with VRd (n=197) or VRd alone (n=195). 
> The median duration of treatment was 56.3 months (0.1 to 64.6 months) for 
> DARZALEX FASPRO-VRd and 34.3 months (0.5 to 63.8 months) for VRd.
> Serious adverse reactions occurred in 72% of patients who received 
> DARZALEX FASPRO-VRd. The most frequent serious adverse reactions in >5% 
> of patients who received DARZALEX FASPRO-VRd were pneumonia (19%), 
> COVID-19 (12%), thromboembolism (7%), and diarrhea (6%). Fatal adverse 
> reactions occurred in 16.8% of patients who received DARZALEX FASPRO-VRd. 
> Fatal adverse reactions that occurred in more than 1 patient included 
> pneumonia (4%), COVID-19 (4%), and myocardial infarction (2%).
> Permanent treatment discontinuation due to an adverse reaction occurred in 
> 8% of patients who received DARZALEX FASPRO-VRd. An adverse reaction 
> which resulted in permanent discontinuation of DARZALEX FASPRO-VRd in 
> more than 1 patient included pneumonia.
> The most common adverse reactions (≥20%) were upper respiratory tract 
> infection, sensory neuropathy, musculoskeletal pain, diarrhea, fatigue, edema, 
> rash, motor dysfunction, COVID-19, constipation, sleep disorder, cough, 
> pneumonia, renal impairment, dizziness, nausea, urinary tract infection, 
> pyrexia, abdominal pain, dyspnea, decreased appetite, and bruising.”

Source: [DARZALEX: DARZALEX FASPRO®, page 6, captured 2026-11-12](https://www.janssenlabels.com/package-insert/product-monograph/prescribing-information/DARZALEX+Faspro-pi.pdf#page=6)

> “Table 11: Adverse Reactions Reported in ≥20% of Patients Who Received 
> DARZALEX FASPRO-VRd in CEPHEUS
> Adverse Reaction
> DARZALEX FASPRO-VRd 
> (N=197)
> VRd (N=195) 
> All Grades  
> (%)
> Grade 3 or 4 
> (%)
> All Grades  
> (%) 
> Grade 3 or 4  
> (%)
> Infections
> Upper respiratory 
> tract infection<sup>a</sup>
> 75
> 4<sup>#</sup>
> 63
> 3<sup>#</sup>
> COVID-19<sup>b</sup>
> 39@
> 9
> 25@
> 3
> Pneumonia<sup>c</sup>
> 31@
> 16
> 26@
> 15
> Urinary tract 
> infection<sup>b</sup>
> 24
> 4<sup>#</sup>
> 17
> 3<sup>#</sup>
> Nervous system disorders
> Sensory 
> neuropathy<sup>d</sup>
> 72
> 12<sup>#</sup>
> 72
> 10
> Motor dysfunction<sup>e</sup>
> 44
> 11<sup>#</sup>
> 37
> 7<sup>#</sup>
> Dizziness<sup>b</sup>
> 26
> 2<sup>#</sup>
> 26
> 1<sup>#</sup>
> Musculoskeletal and connective tissue disorders
> Musculoskeletal 
> pain<sup>b</sup>
> 62
> 9<sup>#</sup>
> 61
> 7<sup>#</sup>
> Table 11: Adverse Reactions Reported in ≥20% of Patients Who Received 
> DARZALEX FASPRO-VRd in CEPHEUS (continued)
> Adverse Reaction
> DARZALEX FASPRO-VRd 
> (N=197)
> VRd (N=195) 
> All Grades  
> (%)
> Grade 3 or 4 
> (%)
> All Grades  
> (%) 
> Grade 3 or 4  
> (%)
> Gastrointestinal disorders
> Diarrhea<sup>b</sup>
> 57
> 12<sup>#</sup>
> 59
> 9<sup>#</sup>
> Constipation
> 38
> 2<sup>#</sup>
> 42
> 3<sup>#</sup>
> Nausea
> 25
> 0
> 25
> 2<sup>#</sup>
> Abdominal pain<sup>b</sup>
> 23@
> 1
> 17
> 2<sup>#</sup>
> General disorders and administration site conditions
> Fatigue<sup>b</sup>
> 56
> 14<sup>#</sup>
> 53
> 11<sup>#</sup>
> Edema<sup>b</sup>
> 54
> 4<sup>#</sup>
> 46
> 2<sup>#</sup>
> Pyrexia<sup>b</sup>
> 24
> 1<sup>#</sup>
> 16
> 1<sup>#</sup>
> Skin and subcutaneous tissue disorders
> Rash<sup>b</sup>
> 50
> 8<sup>#</sup>
> 47
> 7
> Psychiatric disorders
> Sleep disorder<sup>b</sup>
> 33
> 3<sup>#</sup>
> 33
> 2<sup>#</sup>
> Respiratory, thoracic and mediastinal disorders
> Cough<sup>b</sup>
> 32
> 1<sup>#</sup>
> 21
> 1<sup>#</sup>
> Dyspnea<sup>b</sup>
> 21@
> 2
> 17
> 1<sup>#</sup>
> Renal and urinary disorders
> Renal impairment<sup>f</sup>
> 26
> 7
> 25
> 6
> Metabolism and nutrition disorders
> Decreased 
> appetite
> 21
> 1<sup>#</sup>
> 20
> 3<sup>#</sup>
> Injury, poisoning and procedural complications
> Bruising<sup>b</sup>
> 20
> 0
> 12
> 0”

Source: [DARZALEX: DARZALEX FASPRO®, page 6, captured 2026-11-12](https://www.janssenlabels.com/package-insert/product-monograph/prescribing-information/DARZALEX+Faspro-pi.pdf#page=6)

> “<sup>#</sup>	 Only Grade 3 adverse reactions occurred.”

Source: [DARZALEX: DARZALEX FASPRO®, page 6, captured 2026-11-12](https://www.janssenlabels.com/package-insert/product-monograph/prescribing-information/DARZALEX+Faspro-pi.pdf#page=6)

> “@	Fatal adverse reactions occurred for Abdominal pain: n=1 (1%) in the 
> DARZALEX FASPRO-VRd arm; COVID-19: n=7 (4%) in the DARZALEX FASPRO-VRd 
> arm and n=5 (3%) in the VRd arm; Pneumonia: n=8 (4%) in the 
> DARZALEX FASPRO-VRd arm and n=5 (3%) in the VRd arm; Dyspnea: n=1 
> (1%) in the DARZALEX FASPRO-VRd arm.”

Source: [DARZALEX: DARZALEX FASPRO®, page 6, captured 2026-11-12](https://www.janssenlabels.com/package-insert/product-monograph/prescribing-information/DARZALEX+Faspro-pi.pdf#page=6)

Note: Table 11 columns are DARZALEX FASPRO-VRd (N=197) All Grades and Grade 3 or 4, then VRd (N=195) All Grades and Grade 3 or 4 (%).

<a id="darzalex-perseus-side-effects"></a>

### What are the side effects of Darzalex Faspro with VRd for transplant-eligible patients (PERSEUS)?

Applies to: Newly diagnosed multiple myeloma, eligible for autologous stem cell transplant: DARZALEX FASPRO + VRd induction and consolidation vs VRd (PERSEUS)

> “The safety of DARZALEX FASPRO in combination with bortezomib, lenalidomide 
> and dexamethasone (n=351) from the start of induction to the end of consolidation 
> compared to bortezomib, lenalidomide and dexamethasone (VRd) (n=347) 
> was evaluated in PERSEUS [see Clinical Studies (14.1)]. Patients received 
> DARZALEX FASPRO 1,800 mg/30,000 units administered subcutaneously once 
> weekly from weeks 1 to 8 and once every 2 weeks from weeks 9 to 16 during 
> induction in combination with VRd or VRd alone. After week 16, patients 
> underwent stem cell mobilization, high dose chemotherapy, and ASCT. 
> Within 12 weeks of ASCT, and when engraftment was complete, patients 
> received DARZALEX FASPRO once every 2 weeks from weeks 1 to 8 during 
> consolidation in combination with VRd or VRd alone.
> The median duration of treatment for induction and consolidation was 9.9 months 
> (0.5 to 18.5 months) for DARZALEX FASPRO-VRd.
> Serious adverse reactions occurred in 37% of patients who received 
> DARZALEX FASPRO-VRd. The most frequent serious adverse reaction in >5% of 
> patients who received DARZALEX FASPRO-VRd was pneumonia (6%). Fatal adverse 
> reactions occurred in 1.7% of patients who received DARZALEX FASPRO-VRd.
> Permanent treatment discontinuation due to an adverse reaction occurred in 2% 
> of patients who received DARZALEX FASPRO-VRd. An adverse reaction which 
> resulted in permanent discontinuation of DARZALEX FASPRO-VRd in more than 
> 1 patient included sepsis.
> The most common adverse reactions (≥20%) were peripheral neuropathy, 
> fatigue, upper respiratory infection, constipation, musculoskeletal pain, 
> insomnia, rash, diarrhea, edema, and pyrexia.”

Source: [DARZALEX: DARZALEX FASPRO®, page 5, captured 2026-11-12](https://www.janssenlabels.com/package-insert/product-monograph/prescribing-information/DARZALEX+Faspro-pi.pdf#page=5)

> “Table 9: Adverse Reactions (≥10%) in Patients Who Received  
> DARZALEX FASPRO-VRd through the End of Consolidation in PERSEUS
> Adverse Reaction
> DARZALEX FASPRO-VRd 
> (N=351) 
> VRd (N=347)
> All Grades 
> (%)
> Grade 3 or 4
> (%)
> All Grades
> (%)
> Grade 3 or 4
> (%)
> Nervous system disorders
> Peripheral 
> neuropathy<sup>a</sup>
> 52
> 5
> 54
> 4
> Paresthesia
> 11
> <1<sup>#</sup>
> 11
> <1<sup>#</sup>
> General disorders and administration site conditions
> Fatigue<sup>b</sup>
> 35
> 3<sup>#</sup>
> 37
> 5<sup>#</sup>
> Edema<sup>b</sup>
> 22
> 1
> 21
> 1<sup>#</sup>
> Pyrexia
> 21
> 2<sup>#</sup>
> 22
> 3<sup>#</sup>
> Infections
> Upper respiratory 
> tract infection<sup>c</sup>
> 32
> 1<sup>#</sup>
> 26
> 2<sup>#</sup>
> Pneumonia<sup>d</sup>
> 14
> 9
> 10
> 6@
> Gastrointestinal disorders
> Constipation
> 31
> 2<sup>#</sup>
> 30
> 2<sup>#</sup>
> Diarrhea
> 23
> 3<sup>#</sup>
> 25
> 5<sup>#</sup>
> Nausea
> 16
> 1<sup>#</sup>
> 12
> 1<sup>#</sup>
> Abdominal pain<sup>b</sup>
> 11
> 0
> 12
> 0
> Musculoskeletal and connective tissue disorders
> Musculoskeletal 
> pain<sup>b</sup>
> 26
> 1<sup>#</sup>
> 23
> 1<sup>#</sup>
> Muscle spasm
> 12
> 0
> 9
> <1<sup>#</sup>
> Psychiatric disorders
> Insomnia
> 26
> 2<sup>#</sup>
> 16
> 2<sup>#</sup>
> Skin and subcutaneous tissue disorders
> Rash<sup>b</sup>
> 25
> 3<sup>#</sup>
> 31
> 5
> Hepatobiliary disorders
> Hepatotoxicity<sup>e</sup>
> 16
> 6<sup>#</sup>
> 16
> 5
> Respiratory, thoracic and mediastinal disorders
> Cough<sup>b</sup>
> 12
> <1<sup>#</sup>
> 8
> 0”

Source: [DARZALEX: DARZALEX FASPRO®, page 5, captured 2026-11-12](https://www.janssenlabels.com/package-insert/product-monograph/prescribing-information/DARZALEX+Faspro-pi.pdf#page=5)

> “<sup>#</sup>	 Only Grade 3 adverse reactions occurred.”

Source: [DARZALEX: DARZALEX FASPRO®, page 5, captured 2026-11-12](https://www.janssenlabels.com/package-insert/product-monograph/prescribing-information/DARZALEX+Faspro-pi.pdf#page=5)

> “@	Fatal adverse reactions included Pneumonia: n=1 (0.3%) in the VRd arm.”

Source: [DARZALEX: DARZALEX FASPRO®, page 5, captured 2026-11-12](https://www.janssenlabels.com/package-insert/product-monograph/prescribing-information/DARZALEX+Faspro-pi.pdf#page=5)

Note: Table 9 columns are DARZALEX FASPRO-VRd (N=351) All Grades and Grade 3 or 4, then VRd (N=347) All Grades and Grade 3 or 4 (%), through the end of consolidation.

<a id="darzalex-maia-discontinuation"></a>

### How many patients stop Darzalex (DRd) because of side effects (MAIA)?

Applies to: Newly diagnosed multiple myeloma, ineligible for autologous stem cell transplant: DARZALEX + lenalidomide + dexamethasone (DRd) vs Rd (MAIA)

> “Discontinuation rates due to any adverse event: 7% with DRd vs 16% with Rd<sup>2</sup>”

Source: [DARZALEX: DRd Side Effects, captured 2026-11-12](https://www.darzalexhcp.com/triplet/maia/safety/#:~:text=Discontinuation%20rates%20due%20to%20any,with%20DRd%20vs%2016%25%20with)

> “<sup>*</sup>Median duration of study treatment was 25.3 months (range: 0.1–40.44 months) in the DRd group and 21.3 months (range: 0.03–40.64 months) in the Rd group.<sup>1</sup>”

Source: [DARZALEX: DRd Side Effects, captured 2026-11-12](https://www.darzalexhcp.com/triplet/maia/safety/#:~:text=duration%20of%20study%20treatment%20was,0.03%E2%80%9340.64%20months%29%20in%20the%20Rd)

> “You are now viewing a follow-up analysis of the MAIA study. This information is not included in the current Prescribing Information and has not been evaluated by the FDA. TEAEs are reported as observed. The follow-up analysis was not adjusted for multiplicity and conclusions should not be drawn.”

Source: [DARZALEX: DRd Side Effects, captured 2026-11-12](https://www.darzalexhcp.com/triplet/maia/safety/#:~:text=You%20are%20now%20viewing%20a,conclusions%20should%20not%20be%20drawn.)

> “Cumulative rates of discontinuation due to TEAEs were 15% for DRd vs 24% for Rd<sup>3</sup>”

Source: [DARZALEX: DRd Side Effects, captured 2026-11-12](https://www.darzalexhcp.com/triplet/maia/safety/#:~:text=Cumulative%20rates%20of%20discontinuation%20due,for%20DRd%20vs%2024%25%20for)

> “<sup>*</sup>Median follow-up was 64.5 months.<sup>3</sup>”

Source: [DARZALEX: DRd Side Effects, captured 2026-11-12](https://www.darzalexhcp.com/triplet/maia/safety/#:~:text=follow%2Dup%20was%2064.5)

Note: The Safety Over Time page of the Darzalex HCP site reports, in a subset analysis by treatment duration (to approximately 30 months) that is not in the Prescribing Information, has not been evaluated by the FDA, and from which the page states no conclusions should be drawn, that 13% of intent-to-treat patients discontinued treatment due to a TEAE with DARZALEX + Rd (n=364) vs 22% with Rd alone (n=365).

<a id="darzalex-long-term-side-effects"></a>

### What are the long-term side effects of Darzalex (DRd) in MAIA?

Applies to: Newly diagnosed multiple myeloma, ineligible for autologous stem cell transplant: DARZALEX + lenalidomide + dexamethasone (DRd) vs Rd (MAIA)

> “You are now viewing a follow-up analysis of the MAIA study. This information is not included in the current Prescribing Information and has not been evaluated by the FDA. TEAEs are reported as observed. The follow-up analysis was not adjusted for multiplicity and conclusions should not be drawn.”

Source: [DARZALEX: DRd Side Effects, captured 2026-11-12](https://www.darzalexhcp.com/triplet/maia/safety/#:~:text=You%20are%20now%20viewing%20a,conclusions%20should%20not%20be%20drawn.)

> “Cumulative rates of discontinuation due to TEAEs were 15% for DRd vs 24% for Rd<sup>3</sup>”

Source: [DARZALEX: DRd Side Effects, captured 2026-11-12](https://www.darzalexhcp.com/triplet/maia/safety/#:~:text=Cumulative%20rates%20of%20discontinuation%20due,for%20DRd%20vs%2024%25%20for)

> “Cumulative Grade 3/4 infection rates were 43% for DRd vs 30% for Rd<sup>3†</sup>”

Source: [DARZALEX: DRd Side Effects, captured 2026-11-12](https://www.darzalexhcp.com/triplet/maia/safety/#:~:text=Cumulative%20Grade%203%2F4%20infection%20rates%20were%2043%25%20for%20DRd%20vs%2030%25%20for)

> “<sup>*</sup>Median follow-up was 64.5 months.<sup>3</sup>”

Source: [DARZALEX: DRd Side Effects, captured 2026-11-12](https://www.darzalexhcp.com/triplet/maia/safety/#:~:text=follow%2Dup%20was%2064.5)

> “You are now viewing a subset analysis by treatment duration of the MAIA trial. This information is not included in the current Prescribing Information and has not been evaluated by the FDA. No conclusions should be drawn. In the following analysis, treatment-emergent adverse events are presented as observed and should be understood in context with the specific methodology.”

Source: [DARZALEX: Treatment Duration Safety, captured 2026-11-12](https://www.darzalexhcp.com/duration/safety-over-time/#:~:text=You%20are%20now%20viewing%20a,context%20with%20the%20specific%20methodology.)

> “Decrease in adverse event (AE) rates over time from treatment initiation was observed for most AEs in both treatment arms. Cataract tended to increase over time in both treatment arms (see rates on next tab)”

Source: [DARZALEX: Treatment Duration Safety, captured 2026-11-12](https://www.darzalexhcp.com/duration/safety-over-time/#:~:text=Decrease%20in%20adverse%20event%20%28AE%29,%28see%20rates%20on%20next%20tab%29)

Note: The first four passages are from the follow-up safety analysis on the MAIA safety page; the last two are from the Safety Over Time page, whose subset analysis covers patients who continued treatment from treatment initiation to approximately 30 months. The most frequent TEAEs of the follow-up analysis appear on the page only as a figure.

<a id="darzalex-postmarketing-side-effects"></a>

### What side effects have been reported with Darzalex since approval?

> “6.2	 Postmarketing Experience
> The following adverse reactions have been identified during post-approval 
> use of daratumumab. Because these reactions are reported voluntarily from a 
> population of uncertain size, it is not always possible to reliably estimate their 
> frequency or establish a causal relationship to drug exposure.
> Immune System disorders: Anaphylactic reaction, IRR (including deaths)
> Gastrointestinal disorders: Pancreatitis
> Infections: Cytomegalovirus, Listeriosis”

Source: [DARZALEX: DARZALEX®, page 9, captured 2026-11-12](https://www.janssenlabels.com/package-insert/product-monograph/prescribing-information/DARZALEX-pi.pdf#page=9)

> “6.2	 Postmarketing Experience
> The following adverse reactions have been identified with post-approval use 
> of daratumumab. Because these reactions are reported voluntarily from a 
> population of uncertain size, it is not always possible to reliably estimate their 
> frequency or establish a causal relationship to drug exposure.
> Immune System: Anaphylactic reaction, Systemic administration reactions 
> (including death)
> Gastrointestinal: Pancreatitis
> Infections: Cytomegalovirus, Listeriosis”

Source: [DARZALEX: DARZALEX FASPRO®, page 12, captured 2026-11-12](https://www.janssenlabels.com/package-insert/product-monograph/prescribing-information/DARZALEX+Faspro-pi.pdf#page=12)

Note: The first passage is from the DARZALEX (intravenous) Prescribing Information; the second is from the DARZALEX FASPRO Prescribing Information.

## Related pages
- [Medical information: Darzalex (daratumumab): Multiple myeloma](https://www.evicenter.com/medical-information/darzalex--multiple-myeloma)
- [Indication](https://www.evicenter.com/medical-information/darzalex--multiple-myeloma/indication)
- [Pharmacology](https://www.evicenter.com/medical-information/darzalex--multiple-myeloma/pharmacology)
- [Clinical trials](https://www.evicenter.com/medical-information/darzalex--multiple-myeloma/clinical-trials)
- [Drug interactions](https://www.evicenter.com/medical-information/darzalex--multiple-myeloma/drug-interactions)
- [Dosing and administration](https://www.evicenter.com/medical-information/darzalex--multiple-myeloma/dosing-and-administration)
- [Storage and supply](https://www.evicenter.com/medical-information/darzalex--multiple-myeloma/storage-and-supply)
- [Guidelines](https://www.evicenter.com/medical-information/darzalex--multiple-myeloma/guidelines)
